LCB84
As of the edition of 20 October 2026, LCB84 is a drug known only by a code name: in active development; acts on TACSTD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Mouth and teeth; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACSTD2 | Tumor-associated calcium signal transducer 2 | P09758 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| LigaChem Biosciences | Lead sponsor of trials | 2023 to now |